A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects
with Advanced or Metastatic Solid Tumors
This clinical study from NextCure, Inc., is a “first in human testing” study using a drug labeled
NC762-01. This study is designed to evaluate the tolerability and benefits of NC762 in
increasing doses to subjects with refractory solid tumors.
NC762-01 is a new type of immunotherapy drug that will improve the immune system’s ability
to control tumor development and growth. The FDA has approved seven immunotherapy drugs
to date. There are still many patients who do not respond to these drugs. NC762 targets other
pathways that hopefully will lead to better results.
Our dedicated physicians and staff are determined to bring the latest advances in medical
research here so you don’t have to go elsewhere for world class medicine. Gettysburg Cancer
Center is the first site in the world to treat a patient with this promising new drug.
If you are interested in more information on this study, please contact us. Refer to the NextCure
Study Protocol NC762-01. You can also find information on this study by going to
clinicaltrials.gov website and searching for NCT04875806.